Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.42 USD | +0.77% | +4.30% | -26.57% |
Financials (USD)
Sales 2024 * | 529M | Sales 2025 * | 681M | Capitalization | 3.09B |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 120M | EV / Sales 2024 * | 6.1 x |
Net Debt 2024 * | 139M | Net Debt 2025 * | 24.31M | EV / Sales 2025 * | 4.57 x |
P/E ratio 2024 * |
-1,717
x | P/E ratio 2025 * |
26.9
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | +0.77% | ||
1 week | +4.30% | ||
Current month | +4.30% | ||
1 month | -11.09% | ||
3 months | -19.85% | ||
6 months | -11.02% | ||
Current year | -26.57% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 0 M€ | -3.76% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 10.42 | +0.77% | 2,876,127 |
24-05-06 | 10.34 | -0.58% | 1,084,138 |
24-05-03 | 10.4 | -0.29% | 1,379,309 |
24-05-02 | 10.43 | 0.00% | 2,576,847 |
24-05-01 | 10.43 | +4.40% | 3,980,290 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.57% | 3.09B | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+49.22% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- FOLD Stock